University Urology Now Offering iTind Procedure for Novel BPH Treatment

NEW YORK - Dec. 14, 2020 - PRLog -- Dr. Jed Kaminetsky at University Urology is now using the iTind procedure to treat the symptoms of enlarged prostate. The iTind received FDA de Novo classification as a novel device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) in February 2020.

BPH, also known as an enlarged prostate, is one of the most common diseases in aging men and the most common cause of lower urinary tract symptoms (LUTS). According to the American Urological Association, BPH is a condition that 8 out of 10 men will face in their lifetimes, with more than half of men over the age of 50 showing symptoms.[ii]  The iTind procedure reshapes the anatomy of the prostatic urethra, gently creating a wider opening for urine to flow freely, without burning or cutting out tissue, and without leaving behind a permanent implant. The treatment is straightforward, does not require overnight hospitalization, and has none of the side effects associated with prescription medication.

"We are pleased to add the iTind procedure to our treatment portfolio for patients with BPH," says Dr. Kaminetsky. "The iTind gives patients at University Urology the option to choose a less invasive treatment with no major side effects."ⁱⁱⁱ

For more information about University Urology's new BPH treatment using the iTind, please call 212-686-9015 or visit University Urology at https://www.universityurology.com/.

----

Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3), 148–151. doi:10.1016/j.ajur.2017.06.004

[ii] Medical Student Curriculum: Benign Prostatic Hyperplasia (BPH). Auanet.org. https://www.auanet.org/education/auauniversity/medical-st.... Published May 2013, Updated July 2016. Accessed March 3, 2020.

[iii] Kadner G, Valerio M, Giannakis I, Manit A, Lumen N, Ho BSH, Alonso S, Schulman C, Barber N, Amparore D, Porpiglia F. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol. 2020 Mar 2. PMID: 32124019.